{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:06:45Z","timestamp":1794049605049,"version":"4.8.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1097\/wnf.0b013e3181633497","type":"journal-article","created":{"date-parts":[[2008,10,30]],"date-time":"2008-10-30T07:10:03Z","timestamp":1225350603000},"page":"41-47","source":"Crossref","is-referenced-by-count":86,"title":["Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis"],"prefix":"10.1097","volume":"32","author":[{"given":"Massimiliano","family":"Aragona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Onesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Pantano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Inghilleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210203","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0376-8716(96)01277-X","article-title":"A community survey of adverse effects of cannabis use.","volume":"42","author":"Thomas","year":"1996","journal-title":"Drug Alcohol Depend"},{"key":"R2-9-20210203","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1360-0443.2004.00806.x","article-title":"Early adolescent cannabis exposure and positive and negative dimensions of psychosis.","volume":"99","author":"Stefanis","year":"2004","journal-title":"Addiction"},{"key":"R3-9-20210203","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","article-title":"The psychotomimetic effect of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.","volume":"29","author":"D'Souza","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"R4-9-20210203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/bmj.38267.664086.63","article-title":"Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people.","volume":"330","author":"Henquet","year":"2005","journal-title":"BMJ"},{"key":"R5-9-20210203","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/070674370605100903","article-title":"Is cannabis use a contributory cause of psychosis?","volume":"51","author":"Degenhardt","year":"2006","journal-title":"Can J Psychiatry"},{"key":"R6-9-20210203","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/0269881105049040","article-title":"Cannabis as a risk factor for psychosis: a systematic review.","volume":"19","author":"Semple","year":"2005","journal-title":"J Psychopharmacol"},{"key":"R7-9-20210203","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hup.560","article-title":"Comorbid cannabis use and panic disorder: short term and long term follow-up study.","volume":"19","author":"Dannon","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"R8-9-20210203","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.coph.2004.08.010","article-title":"Long-term effects of exposure to cannabis.","volume":"5","author":"Iversen","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"R9-9-20210203","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00213-002-1169-0","article-title":"Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.","volume":"164","author":"Curran","year":"2002","journal-title":"Psychoparmacol (Berl)"},{"key":"R10-9-20210203","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1097\/00001756-200306110-00009","article-title":"Marijuana alters the human cerebellar clock.","volume":"14","author":"O'Leary","year":"2003","journal-title":"Neuroreport"},{"key":"R11-9-20210203","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/jama.287.9.1123","article-title":"Cognitive functioning of long-term heavy cannabis users seeking treatment.","volume":"287","author":"Solowij","year":"2002","journal-title":"JAMA"},{"key":"R12-9-20210203","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1212\/01.wnl.0000201279.83203.c6","article-title":"Neuropsychological deficits in long-term frequent cannabis users.","volume":"66","author":"Messinis","year":"2006","journal-title":"Neurology"},{"key":"R13-9-20210203","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00213-005-0298-7","article-title":"Long-term effects of frequent cannabis use on working memory and attention: an fMRI study.","volume":"185","author":"Jager","year":"2006","journal-title":"Psychopharmacol (Berl)"},{"key":"R14-9-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/B:NERV.0000026647.71528.83","article-title":"Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse.","volume":"14","author":"Verdejo-Garcia","year":"2004","journal-title":"Neuropsychol Rev"},{"key":"R15-9-20210203","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2165\/00003495-200060060-00005","article-title":"Cannabinoids in clinical practice.","volume":"60","author":"Williamson","year":"2000","journal-title":"Drugs"},{"key":"R16-9-20210203","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/jnnp.2005.075333","article-title":"Cannabinoids in multiple sclerosis: urgent need for long term trials.","volume":"76","author":"Killestein","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R17-9-20210203","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/1352458505070618","article-title":"Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis.","volume":"12","author":"Wade","year":"2006","journal-title":"Mult Scler"},{"key":"R18-9-20210203","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"R20-9-20210203","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0033-3182(71)71479-0","article-title":"A rating instrument for anxiety disorders.","volume":"12","author":"Zung","year":"1971","journal-title":"Psychosomatics"},{"key":"R21-9-20210203","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/135245859900500409","article-title":"The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force.","volume":"5","author":"Fischer","year":"1999","journal-title":"Mult Scler"},{"key":"R22-9-20210203","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.socscimed.2003.10.015","article-title":"Use of a visual analogue scale in a daily patient diary: modelling cross-sectional time-series data on health-related quality of life.","volume":"59","author":"Parkin","year":"2004","journal-title":"Soc Sci Med"},{"key":"R23-9-20210203","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1468-1331.2002.00444.x","article-title":"Measuring fatigue in patients with Parkinson's disease-the Fatigue Severity Scale.","volume":"9","author":"Herlofson","year":"2002","journal-title":"Eur J Neurol"},{"key":"R24-9-20210203","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"key":"R25-9-20210203","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jchromb.2003.12.024","article-title":"Liquid chromatographic-mass spectrometric quantitation of Delta9-tetrahydrocannabinol and two metabolites in pharmacokinetic study plasma samples.","volume":"803","author":"Valiveti","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R26-9-20210203","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1177\/1352458506070624","article-title":"The PASAT performance among patients with multiple sclerosis: analyses of responding patterns using different scoring methods.","volume":"12","author":"Rosti","year":"2006","journal-title":"Mult Scler"},{"key":"R27-9-20210203","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1191\/1352458504ms1048oa","article-title":"Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.","volume":"10","author":"Vaney","year":"2004","journal-title":"Mult Scler"},{"key":"R28-9-20210203","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1212\/01.wnl.0000176753.45410.8b","article-title":"Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.","volume":"65","author":"Rog","year":"2005","journal-title":"Neurology"},{"key":"R29-9-20210203","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1192\/bjp.187.4.306","article-title":"Cannabis use and misuse prevalence among people with psychosis.","volume":"187","author":"Green","year":"2005","journal-title":"Br J Psychiatry"},{"key":"R30-9-20210203","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.38149.566979.AE","article-title":"Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.","volume":"31","author":"Svendsen","year":"2004","journal-title":"BMJ"},{"key":"R31-9-20210203","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1191\/1352458504ms1048oa","article-title":"Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.","volume":"10","author":"Vaney","year":"2004","journal-title":"Mult Scler"},{"key":"R32-9-20210203","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1212\/01.wnl.0000176753.45410.8b","article-title":"Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.","volume":"65","author":"Rog","year":"2005","journal-title":"Neurology"},{"key":"R33-9-20210203","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1468-1331.2006.01639.x","article-title":"Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.","volume":"14","author":"Collin","year":"2007","journal-title":"Eur J Neurol"},{"key":"R34-9-20210203","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/1352458506070947","article-title":"Cannabis use in patients with multiple sclerosis.","volume":"12","author":"Chong","year":"2006","journal-title":"Mult Scler"},{"key":"R35-9-20210203","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1192\/bjp.188.2.148","article-title":"Cannabis use and mental health in secondary school children. Findings from a Dutch survey.","volume":"188","author":"Monshouwer","year":"2006","journal-title":"Br J Psychiatry"},{"key":"R36-9-20210203","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1017\/S0033291706009688","article-title":"Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects.","volume":"37","author":"Arendt","year":"2007","journal-title":"Psychol Med"},{"key":"R37-9-20210203","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1212\/WNL.58.9.1404","article-title":"Safety, tolerability, and efficacy of orally administered cannabinoids in MS.","volume":"58","author":"Killestein","year":"2002","journal-title":"Neurology"},{"key":"R38-9-20210203","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1100\/tsw.2003.57","article-title":"Psychoactive drugs and quality of life.","volume":"18","author":"Ventegodt","year":"2003","journal-title":"Sci World J"},{"key":"R39-9-20210203","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/jnnp.2005.070136","article-title":"Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.","volume":"76","author":"Zajicek","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R40-9-20210203","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000112901","article-title":"The perceived effects of smoked cannabis on patients with multiple sclerosis.","volume":"3","author":"Consroe","year":"1997","journal-title":"Eur Neurol"},{"key":"R41-9-20210203","first-page":"923","article-title":"Benzodiazepine dependence.","volume":"33","author":"Khong","year":"2004","journal-title":"Aust Fam Phys"},{"key":"R42-9-20210203","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.genhosppsych.2006.05.008","article-title":"Outcome of new benzodiazepine prescriptions to older adults in primary care.","volume":"28","author":"Simon","year":"2006","journal-title":"Gen Hosp Psychiatry"},{"key":"R43-9-20210203","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1176\/appi.ajp.159.5.881","article-title":"Abuse, dependence, or withdrawal associated with tramadol.","volume":"159","author":"Brinker","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R44-9-20210203","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00002826-200009000-00008","article-title":"Abuse, dependence, and epileptic seizures after zolpidem withdrawal: review and case report.","volume":"23","author":"Aragona","year":"2000","journal-title":"Clin Neuropharmacol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-200901000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:51:16Z","timestamp":1618278676000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200901000-00009"}},"subtitle":["A Double-Blind, Placebo Controlled, Crossover Study"],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3181633497","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}